Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNA, U6 small nuclear 229, pseudogene** (RNU6-229P) is a putative non-functional genomic locus classified as a processed pseudogene derived from the highly conserved U6 small nuclear RNA (snRNA) gene family. U6 snRNA is an essential component of the spliceosomal machinery, involved in intron removal during pre-mRNA splicing in eukaryotes, but **RNU6-229P itself lacks coding potential and is not transcribed into a functional RNA product**[5][7]. U6 snRNA-derived pseudogenes are generated through L1-mediated retrotransposition or related mechanisms, and they reflect genome evolutionary dynamics rather than serving any biological activity[7][1]. There is no evidence that RNU6-229P or similar U6 snRNA pseudogenes function as therapeutic targets, receptors, or enzymes. **Context and clarification:** - RNU6-229P is a member of the large family of U6 snRNA pseudogenes found throughout vertebrate genomes, representing genomic "fossils" of formerly active U6 snRNA genes[5][7]. - Canonical U6 snRNA genes encode non-coding RNAs that are *vital* components of the spliceosome complex and thus essential for RNA splicing and cellular viability[5][3]. - Pseudogenes, including RNU6-229P, arise from the retrotransposition of small nuclear RNAs and do not retain regulatory or coding capacity[7][1]. - As a result, RNU6-229P is not a protein, not a receptor, not druggable, and has no established function in physiology or disease. **Summary:** - RNU6-229P is not a true gene or functional RNA but a **pseudogene derived from U6 snRNA**, undocumented as a therapeutic or biological target. - Listing it as a target is incorrect unless the query concerns evolutionary genomics or markers of retrotransposition events. - It should not be included in receptor/target-oriented pipelines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 229, pseudogene (RNU6-229P).